Dr. Elie Akl, the director of the AUB GRADE center, participated recently in the World Health Organization (WHO) department of Neglected Tropical Disease guidelines on the use of fexinidazole in patients with Human African Trypanosomiasis (HAT). Dr. Akl acted as the GRADE methodologist and co-chair for the guideline.
HAT is a neglected tropical disease that occurs in sub-Saharan Africa, within the distributional limits of its vector, the tsetse fly. It caused devastating epidemics during the 20th century, but thanks to sustained and coordinated efforts over the past 15 years, the number of reported cases has fallen to historically low levels. Fexinidazole is an emerging therapeutic option for HAT that was recently approved by the European Medicines Agency (EMA),
The WHO guideline development group meeting was held on 3-4 December 2018 in the WHO headquarters in Geneva.